Project Grant R21CA307443
Award Date 7/16/26
Completion Date 6/30/28
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $410,933 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on March 18, 2026, with completion anticipated by February 29, 2028. This exploratory research initiative (R21) focuses on developing next-generation small interfering RNA (siRNA) therapeutics to treat metastatic castration-resistant prostate cancer (mCRPC). The primary deliverable is the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a $2.84M Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate improved cancer treatment methodologies. The award, effective August 18, 2025 through July 30, 2029, funds research focused on enhancing the therapeutic efficacy of cyclophosphamide (CPA) and doxorubicin (DOX)-based chemotherapy regimens while minimizing treatment-related toxicity....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $658,423 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026 through June 30, 2031. This award supports fundamental research on therapeutic targeting of PI3K gamma (PI3Kγ)-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC) to reduce health disparities. The research builds on the investigator...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant of $100,228 under the Cancer Research Manpower program (CFDA 93.398) to investigate the molecular mechanisms of MYC-driven transcriptional reprogramming in the prostate cancer tumor microenvironment (TME). The award, effective December 1, 2026 through May 31, 2029, supports research aimed at understanding how the MYC protein functions as a molecular switch that transitions...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, College Park a Project Grant totaling $369,075 under the Cancer Biology Research program (CFDA 93.396) on June 1, 2026, with a completion deadline of May 31, 2028. This grant funds research to reconstruct transposable element activity in cancer through local assembly of long reads. Transposable elements are DNA sequences that copy or relocate within the genome, producing insertions that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Mississippi Medical Center a $517,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) on July 13, 2026, with a completion date of June 30, 2031. This award funds research into the role of protein lipoylation in prostate cancer bone metastasis development. The project investigates the ferredoxin 1 (FDX1)-mediated lipoylation process and its relationship to androgen receptor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $606,219 to the University of Miami's Office of Research Administration–School of Medicine on July 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project through June 30, 2031. The project investigates signal transduction, cell biology, and molecular pharmacology of OR51E1, an olfactory G protein-coupled receptor (GPCR) ectopically expressed in prostate cancer and other...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, to support research on protein degradation strategies to overcome menin inhibitor drug resistance in acute leukemias. The project, which extends through April 30, 2028, focuses on developing proteolysis-targeting chimeras (PROTACs) as a therapeutic approach to address rapid resistance...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Davis a $551,328 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, with completion targeted for March 31, 2031. This research initiative, "Dissecting the Role of CPT1C in Advanced Prostate Cancer," focuses on elucidating the molecular mechanisms and therapeutic potential of carnitine palmitoyltransferase 1C (CPT1C) in neuroendocrine...
- Federal Project Grant Award Summary Yale University received a $142,635 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective June 3, 2026, with completion targeted for May 31, 2028. The award supports research training and workforce development in cancer biology focused on decoding long noncoding RNA (lncRNA) networks that drive lineage plasticity and resistance to androgen receptor (AR)-targeted therapies in...